glp·helper
glphelper.com/mounjaro/mississippi/jackson
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Jackson, MS

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Mounjaro is FDA-approved for type 2 diabetes, not for weight management.[1] The tirzepatide approved for chronic weight management is Zepbound in Jackson.

Physicians near Jackson, MS from the federal NPI registry. Ask each office whether it prescribes Mounjaro.[9]

city providers
38
as of today

Same molecule (tirzepatide): Tirzepatide in Jackson, Zepbound in Jackson

Other GLP-1 medicines: Ozempic in Jackson, Wegovy in Jackson, Semaglutide in Jackson

§ 02Provider directory: Mississippi
38 of 38 shown

Find a Mounjaro provider in Jackson.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Mounjaro by Mississippi town, physicians per town
§ 03Getting Mounjaro in Jackson
38 providers · Jackson, MS

How to get Mounjaro in Jackson.

38 GLP-1 prescribers and 7 local resource types are on record for Jackson, plus 3 nearby towns in the directory.

Physicians in Jackson
38 physicians
38 physicians from the federal NPI registry in Jackson, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (13) and Internal Medicine (9). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Hattiesburg (29 providers), Meridian (30 providers) and Gulfport (27 providers).
Around the prescription in Jackson
7 listed nearby
6 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 3 trainers, 6 physiotherapists and 3 places to move are on record near Jackson.
Medicaid (weight loss)
Covered
As of April 2026, Mississippi Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Mississippi’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

Bar chart of Mounjaro dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Mounjaro comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Zepbound is the tirzepatide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Jackson

Jackson, Mississippi has a population of 153,701 people. The adult obesity rate in Jackson is an age-adjusted estimate of 46.5%, 6.1 percentage points above the Mississippi state rate of 40.4%. Diagnosed diabetes reaches 17.2% of adults in Jackson. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 37.3% of adults in Jackson.

of Jackson adults have obesity
46.5%
diagnosed diabetes
17.2%
no regular physical activity
37.3%

Age-adjusted estimates for Jackson, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Mounjaro in Jackson
3 nutritionists

The prescription is one part. Here is the rest, in Jackson.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Jackson, MS, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tiffani Grant, LD
NUTRITIONIST
Nutritionist · Education
2500 North State Street
Call 601-984-5660NPI 1770770117
Jacinda Roach, RD
NUTRITIONIST
Nutritionist · Education
1860 Chadwick Dr
Call 601-376-1681NPI 1316139181
Lachaka Robinson, Personal Trainer
NUTRITIONIST
Nutritionist
2424 Raymond Rd
Call 601-533-8335NPI 1316533573

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Baptist Healthplex at Mississippi College
FITNESS
4.5 on Google · 202 reviews
102 Clinton Pkwy
Website
Hughes Athletics Field
REC CENTER
4.3 on Google · 170 reviews
545 Ellis Ave
Coyote Fitness Flowood
FITNESS
5.0 on Google · 103 reviews
513 Liberty Rd #2A
Website
Walter Payton Health & Recreation Center
REC CENTER
4.7 on Google · 98 reviews
Address not listed
Quest Fitness
FITNESS
4.4 on Google · 56 reviews
1693 Lakeover Rd
Website
Crossfit 601
FITNESS
4.9 on Google · 48 reviews
210 Industrial Cove
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Mounjaro side effects are stomach and gut effects.

In Mounjaro's diabetes trials at 5 to 15 mg, the most common side effects were nausea (12 to 18%), diarrhea (12 to 17%), decreased appetite (5 to 11%), and vomiting (5 to 9%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 18%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
12 to 17%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
6 to 7%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Mounjaro costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Mounjaro monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
LillyDirect self-payfrom $499per monthListed at the same starting price for every strength, 2.5 mg to 15 mg
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Medicare Part D$0 to $100per monthT2D covered; weight-loss indication not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Mounjaro providers in Jackson

Physicians from the federal NPI registry. Ask each office whether it prescribes Mounjaro.

Mounjaro in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Mounjaro.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Mississippi

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]